<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 349 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page348.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=349">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 349 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 349</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=349"><img src="../thumb/349.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>312 / 2020-04                                                           Endocrine System - 19.8
   Indications: Advanc.oestrog.recept.posit. breast Ca in natural/  positive breast Ca allow.subseq. breast-conserv.surg.in women not   Indications:.Treatm.of pts.with prostat.Ca.in whom androg.dep-
   induc.postmenopaus.status where dis. progress.follow.anti-oes-  origin.consid.for this type of surg.  rivat.warrant.
   trog.ther., adjuv. treatm. of oestrog.recept.posit.invas.early breast   (S4) TABS. 31/21.12/0378.  (S4) PWD.FOR SOL.FOR INJ 43/21.12/0918; 0920
   Ca dis. free postmenopaus.women follow.at least 2 yrs. of init.  831468-009: 2,5 mg, 30, R1 190,44  719141-001: 80 mg, 1 vial + pre-fill.syr.solv., R2 480,60
   adjuv.tamoxifen ther.        Dosage: 2,5 mg once dly. Contin.x5 yrs./until tumour relapse oc-  719136-001: 120 mg, 2 vials + pre-fill.syr.solv., R3 153,77
   (S4) TABS, 45/21.12/0908     curs whichever comes 1 . Contin until tumour progress.is evident   Dosage: For SC admin only. Admin.in abdom.reg. Vary inj.site pe-
                                           st
   720023-001: 25 mg, 30, R1 157,81  in metast.dis.pts.       riodic. Ref.to prod.lit.for usage instructs.
   Dosage: Adults & elderly: 25 mg dly.pref.aft.a meal. In advanc.  Contraindications: Premenopaus.endocrine status, pregn., lactat.,   Adult males: Start.dos: 240 mg admin.as 2xSC. injects. of 120
   breast Ca cont.until tumour progress. evid. In early breast Ca con-  sev.hepat./ren.funct.impairm., childr.  mg each. Maint.dos: 80 mg mnthly. First maint.dos.should be giv.1
   tin.treatm. unt.5 yrs.of adjuv.hormon.ther.complet./until tumour   Side effects: Hot flush., naus., fatig., alopec., arthralg./arthrit.,   mnth.aft.start.dos.
   relapse occurs.              osteoporos., UTI, tumour pain, leucopen., anorex., incr.appetite.,   Contraindications: Women/paed.pts., pregn, QTc durat.&gt;450 msec
   Contraindications: Pre-menopaus.women, pregn. & lactat.  hypercholesterolaem., gen./periph.oed., depress., anx., CNS.effs.,   (eg.congenit. QT prolongat.), concomit.meds.known to prolong QT
   Side effects: Freq: Anorex., insomn., depress., anx., confus.,   headache, dizzin., dysaesthes., taste disturbs., CVA, cataract, eye   time (eg. Class I (eg. procainamide, quinidine) or Class III (eg. ami-
   headache, dizzin., carpal tunnel syndr., hot flush., hypertens., lym-  irrit., blurr.vis., vasc./ card. disords.incl.CF, dyspn., GI disturbs., sto-  odarone, sotalol) antidysrhythm.meds.), hist./ risk factors for torsades
   phoedema, N&V abdom.pain, constipat., dyspeps., diarrh., incr.   matit., incr. hepat.enzym, incr.sweat., skin reacts., myalg., bone pain/-  de pointes, safety &effic.not est.in sev.ren./hepat.impairm., IV admin.
   sweat., skin rash, alopec., itch., paraesthes., joint & musculoskel-  fract., incr.urin.freq., vag.bleed./ discharge/ dryn, breast pain, pyrex.,   Side effects:.Flush, incr.weight, inj.site reacts. incl. pain/ery-
   et. pain incl.arthralg., fatig., pain, periph.oed. Less freq: Somnol.,   mucos.dryn., thirst, weight changes, asthen., malaise.  them./swell./indurat.nodule, anaem., hypersens., insomn., decr.
   osteoporos., fract., pain in limbs, osteoarthrit., back pain, myalg.,   Warnings and special precautions: Concom. admin.of drugs   libid., depress., ment. impairn., blurr.vis., dysrhythm, QT prolongat.,
   joint stiffn., asthen., thrombocytopen., leucopen., lymphocytopen.   whose disposit.mainly depend.on these isoenzymes & with nar-  dizzin., headache, hypoaesthes., hypertens., vasovag. react., N&V,
   Freq.unknown: Infect., URTI, UTI, flu-like sympt., dyspn., bronchit.,   row therapeut.index, imp.ren.funct., no exper.in combinat.with   dry mouth, abdom. pain, constipat., incr.liv.transaminas., musculo-
   chest pain, sinusit., pharyngit., rhinit., hepatit., cholest. jaund. In-  other anti-cancer agents.  skelet. pain/discomf., osteoporos., decr. bone min.dens., arthralg.,
   vestigat: Elev.liv.enzym.,                                 hyperhidros.(incl.night sweats), rash, urticar., skin hyperpigmentat.,
   Warnings and special precautions: Concom. agents that are   FEMZOLE 2,5 (AI Crit Care) AI Ltd  alopec., prurit., erythem., pollakiur., micturit.urg., dysur., noctur., ren.
   substrat.for CYP3A4/narr.therap. index., concom.oestrog.contain.  Letrozole  impairm., incontin., erect. dysfunct., testicul.atroph./pain, gynae-
   meds.would negate pharmacolog.act., not recomm.in childr., con-  Indications: Extend.adjuvant treatm.of early breast Ca in post men-  comast., breast/ pelvic pain, genit.irrit., ejaculat.fail., chills, pyrex.,
   firm post menopaus.status by LH/FSH & oestrad. lev., as bone min.  opaus.women who have rec.prior std. adjuvant tamoxifen ther., first   asthen., fatig., influenza-like illn., periph. oed., hyperglycaem., dia-
   density reduct.poss.with longt.use assess bone min.density init.&   line treatm.in postmenpaus. women with hormone depend.advanc.  bet.mellit., incr. cholest., decr.weight, chang.in bld.Ca, decr. appet.
   reg.dur. ther., osteoporos.prophylax.treatm.init.as appropr. & monit.,   breast Ca, advanc.breast Ca in women with natural/artific. induc.  Warnings and special precautions:. Chang.in bone min.densit.,
   cont.mannitol hav.poss.laxat.eff.  postmenopaus. status prev.treat.with anti-oestrog., pre-op ther.in   anti-degarelix antibod.develop., monit.therapeut. eff.by clinic.para-
   Interactions: Reduc.plasma conc./effic.with CYP izoenzym.in-  postmenopaus.women with localis.horm.recept. positive breast   met.& PSA ser. lev., do not mix with other.medic.prods., wear glov.
   duc. e.g.rifampicin/phenytoin/ carbamazepine/ St John’s Wort.  Ca allow. subseq.breast-conserv. surg.in women not origin.consid.  dur.prep. & admin., no inj.should be giv.in areas where pt.will be
                                for this type of surg.        expos.to press.eg.around belt/waistband/close to ribs.
   EVERDEX 1 mg, AstraZeneca    (S4) TABS, 43/21.12/0734      See also MDR page 323.
   Anastrozole.                 716696-001: 2,5 mg, 30, R509,93
   Indications: Early & advanc.breast Ca in post menopaus. women.   Dosage: Adults incl. elderly: 2,5 mg once dly. Contin.x 5 yrs./un-  KESSAR, Pfizer
   Effic.not demonstrat.in oestrog. recept.negat.pts.unless prev.posit.  til tumour relapse occurs/ whichever comes 1 . Contin.until tumour   Tamoxifen citr.equiv.to tamoxifen.
                                                   st
   clinic. respons.to tamoxifen report.  progress. is evid.in metast.dis.pts.  Indications: Palliat.treatm.for cert.adv.breast tumours, adjuv.ther-
   (S4) TABS. 42/21.12/1096.    Contraindications: Safety in pregn.& lactat.not est., premenopaus.  apy in delay.recurr.follow. total/segment.mastect.& axill.dissect.&
   717608-001: 1 mg, 30, R857,99   endocrine status, sev.liv. funct. impairm. (Child Pugh C), sev.kidn.  breast irradiat.in women with axill.node-negat.breast Ca
   Dosage: Adults incl.elderly: 1 tab.once dly.  funct. impairm. (creatine clear.&lt;10 ml/min.), not recomm.in childr.  (S4) TABS. S/21.12/359.
   Contraindications: Pre-menopaus.women, pregn. & lactat., sev.  Side effects: Bone miner.dens.reduct., UTI, tumour/ bone/breast   735175-004: 20 mg, 30, R141,76
   ren.impairm., mod.to sev. hepat. dis.  pain, leucopen., anorex., incr. appet., hypercholesterolaem., gen.oed.,   Dosage: Init.dos: 20-40 mg/day in 2 div.dos.or as sngl.dly.dos.
   Side effects: V.common: Naus., asthen., arthralg., joint stiffn.,   depress., anx., nervousn., irritabil., headache, dizzin., CNS. effs.incl.   Advanc.dis: contin.treatm.unt. dis. progress. Adjuvant ther.usu-
   arthrit., headache, rash, hot flushes. Common: Diarrh., vomit.,   dysaesthes., memory impairm., CVA, cataract, eye irrit., blurr.vis., MI,   al.min.2yrs., no therapeut. advantage gain.if prolong.past 5 yrs.
   incr.liv. enzymes, anorex., hypercolesterolaem., bone pain, myalg.,   myocard. ischaem., palpitat., tachycard., thrombophlebit., hypertens.,   Contra-indications: Pregn., lactat.
   carpal.tunnel sydr., somnol., sens.disturbs. incl.paraesthes., taste   pulm.embol., arter.thrombos., cerebrovasc. infarct., dyspn., GI dis-  Side-effects: Hot flush., vag.bleed./disch., prurit. vulvae, GI intol.,
   loss & pervers., vag.dry.& bleed., alopec., allerg.reacts. Uncom-  turbs., stomatit., dry mouth, incr.hepat.enzym., alopec., incr.sweat.,   lightheadedn., fluid retent., weight gain, rash., bld.dyscras, tumour
   mon: Incr. gamma-GT & bilirub., hepatit., hypercalcaem., trigg.   skin reacts., arthralg., myalg., bone fract., osteoporos., incr.urin.freq.,   pain in pts. with bone metastases combin.with hypercalcaem, men-
   fing., urticar. Rare: Erythema multiform., anaphylact. react., cutan.  vag.bleed./ discharge/ dryn., hot flush., periph.oed., pyrex., mucos.   str.irregularit., cyst.ovar.swell., headache, depress., confus., mus-
   vasculit. V.rare: Stev. John.syndr., angioed. Thromboembol., fluid   dryn., thirst, fatig.incl.aesthen., weight chang.  culo-skelet.pain, alopec., dry skin, vis.disturbs., sev.liv.abnormalit.
   retent. & dizzin.also observ.  Special precautions: Monit.bone min.density in pts.with/at risk of   Special precautions: Reg.serum Ca estimat., women with funct.
   Warnings and special precautions: As circulat. oestrog.lev.  osteoporos./fract.at start of & dur. ther., osteoporos.treatm./prophy-  ovaries, thromboembol. disords., incr.incid.of endometr.chang.report,
   low.poss.reduc.bone min. density with conseq.incr.fract.risk, no   lax.as appropr. & monit., concom.admin.of drugs whose disposit.   pregn., compl.gynaecolog.exam.bef.& rep.dur. treatm., discont.&
   clinic. info.on other concom.anti-cancer agents use, not recomm.  mainly depend.on P450-isoenzymes 2A6 & 2C19 & with narrow   take appropr.meas.if hypercalcaem. occurs, vary oestrog.effs.on
   in childr., consid.furth.eval.of persist.vag. bleed., ischaem.CV events   therapeut.index, cont.lact.  Pap. smear in post-menopaus.pts.
   more freq.than in tamoxifen treat.pts., biochem.confirmat.of meno-  Drug interactions: Incr.anti-coag.eff.with coumar.-like anticoags.,
   pause if in doubt, galact./lact.intol.  FINCAR 5, Cipla Medpro [P/S]  meds.decr.ren.Ca excret. incr.hypercalcaem.risk, aminoglutethimides
   Interactions: Tamoxifen &/other oestrog.contain. ther. would   Finasteride.  reduc. serum lev., bromocriptine incr.serum lev.
   dimin.pharm.act.             Indications: Benign prostat.hyperplas.(BPH).  LARADEX, Eurolab
   FASLODEX, AstraZeneca        (S4) TABS. 41/21.12/0422      Letrozole
                                709473-001: 5 mg, 30, R324,25
   Fulvestrant                  Dosage: 5 mg dly. 6-12 mnth.ther.poss.necess.to access respons.  Indications: First line treatm.in postmenpaus. women with advanc.
   Indications: Oestrog.recept.posit.loc.advanc. /metastat. breast   Contraindications: Pregn./poss.pregn., use in women/childr.,   breast Ca, hormone depend advanc.breast Ca in women with natu-
   Ca in postmenopaus.women not prev. treat.with endocr.ther.or   safety dur.breast feed.not est.  ral/ artific. induc. postmenopaus.status prev.treat.with anti-oestrog.,
   with dis.relapse on or aft.adjuv.anti-oestrog.ther./dis.progress.  Side effects: Impot., decr.libido, ejaculat.disords., breast enlargem/  pre-op ther.in postmenopaus.women with localis.oestrog.recept.
   on anti-oestrog.ther.        tendern., testic.pain, rash, hypersens. reacts.incl.fac.& lip swell., S-  positive breast Ca allow. subseq.breast-conserv.surg.in women not
   (S4) INJ, A38/21.12/0656.    PSA values decr.in treat.pts.  origin.consid.for this type of surg.
   707442-002: 250 mg/5 ml, 2xpre-fill.syr., R11 334,87  Special precautions: Poss.abnormalitit.to ext. genital.of male foe-  (S4) TABS. 42/21.12/0324.
   Dosage: Long-act.formula. Do not mix.with other meds.  tus, expos.to crush/brok.tabs.by pregn./poss.pregn.women, pres.in   715718-001: 2,5 mg, 30, R511,49
   Adult females incl.elderly: 500 mg slow IMI as two 5 ml inj.at 1   semen theref. male pts.to use condoms/avoid fem.partn.at risk of   Dosage: Adults incl.elderly: 2,5 mg once dly. Contin.until tumour
   mnth interv.with addit.500 mg dos.2 wks.aft.init.dos.  becom.pregn., monit.for obstruct.uropathy, prostate Ca screen prior   progress.is evident
   Contraindications: Sev.hepat.impairm., pregn., lactat.  to init.& dur.ther., eval.pts with sustain. incr.in S-PSA lev.careful.  Contraindications: Premenopaus.endocrine status, safety in
   Side effects: V.common: Inj.site reacts., sciatica, neuralg., neu-  pregn.& lactat.not est., sev. hepat.funct.impairm.(Child Pugh C),
   ropath.pain, periph. neuropathy, asthen., elev.liv.enzym., naus.,   FINPECIA, Cipla-Medpro [P/S]  creatine clear.&lt;10 ml/min., childr.
   angioed., urticar., arthralg., musculoskelet.pain, back pain, myalg.,   Finasteride.  Side effects: UTI, tumour pain in metastat./ neoadjuv. setting, leu-
   extremity pain, rash, hot flshes. Common: Headache, elev.bilirub.,   Indications: Temp.delays further hair loss & incr.hair dens.in the   copen., angioed., anaphylact. react., anorex., incr.appet., rais.ser.cho-
   reduc.platel. count, vomit., diarrh., anorex., UTI. Uncommon: Elev.  vertex & anterior mid scalp area in men betw.18 & 41 yrs.with early   lester., oed., depress., anx., nervousn., irritabil., headache, dizzin.,
   gamma-GT. Post market: Hepatobil.disords., hepat. fail. & hepatit.  signs of androgenet.alopec.  CNS.effs.incl.dysaesthes./paraesthes./ hypoaesthes., taste pervers.,
   Warnings and special precautions: Mild to mod. hepat.im-  (S4) TABS, 41/21.12/0221  CVA, cataract, eye irrit., blurr.vis., palpitat., tachycard., thrombophle-
   pairm., creatin.clear.&lt;30 ml/min., bleed. diatheses/thrombocyto-  709848-001: 1 mg, 30, R166,18  bit., hypertens., ischaem.card.events, pulm. embol., arter.thrombos.,
   pen.& anticoag. ther.due to route of admin., underly.sciat.nerve   Dosage: 1 mg dly. Use for 3 mnths.or more necess. bef./incr.hair   cerebrovasc.infarct., dyspn., cough, GI disturbs., stomatit., dry mouth,
   proximity when admin.IMI, reproduct.toxic.in animals & found in   growth &/prev.of further hair loss observ. Contin.use recomm.  incr. hepat.enzym., hepatit., alopec., incr.sweat., skin reacts.incl.tox.
   rats’ milk at signif.high.lev.than in rat plasma, safety & effectiven.  for max benef.  epiderm.necrolys., erythema multiforme, arthralg., myalg., bone
   in childr./ adolesc. not est.  Contraindications: Pregn./poss.pregn., lactat., women/childr.,   pain, osteoporos., bone fract., arthrit., incr.urin.freq., vag. bleed./-
   Interactions: Falsely incr.oestradiol lev.from interfer.with antibody-  safety & effic.in elderly not est.  discharge/-dryn, breast pain, hot flush., fatig.incl.aesthen., periph.
   bas.oestrad.assays.          Side effects: S-PSA lev.decr., impot., decr.libido, decr. ejaculat.vol.,   oed., pyrex., mucos. dryn., thirst, weight incr./loss.
   FEMARA, Novartis             ejaculat.disord., breast tendern. / enlargem., testicul.pain, rash, hy-  Drug interactions: No exper.in combinat.with other anti-can-
                                persens.reacts. incl.fac./lip swell.
                                                              cer agents.
   Letrozole.                   Special precautions: Pregn./potent. pregn. women not to handle
   Indications:Adjuvant treatm.of postmenopaus. women with hor-  brok./crush.tabs.due to risk to male foetus, pres.in semen theref.use   MIFEGYNE, Medi Challenge [P/S]
   mone recept.posit.early breast Ca, extend.adjuvant treatm.of early   condom/ avoid expos.to fem.sex.partn.at risk of pregn., abnorm. to   Mifepristone
   breast Ca in post menopaus.women who have rec.prior std. adjuvant   ext.genitil.of male foetus when admin. dur.pregn., effs.revers.with-  Indications: Medic.alternat.to surg.terminat.of intrauter.pregn.of
   tamoxifen ther., first line treatm.in postmenpaus. women with hor-  in 12 mnths.of withdr., 50 % decr.of S-PSA in old.men with BPH.  up to 56 days in combinat.with prostaglandin analogue, soften.&
   mone depend.advanc.breast Ca, advanc.breast Ca in women with   dilat.of cervix. prior to surg.pregn.terminat, terminat.of pregn.of
   natural/artific. induc.postmenopaus.status prev.treat.with anti-oes-  FIRMAGON, Ferring [P/S] &  betw.13-20 wks.in combinat.with prostaglandin analogue, expuls.
   trog., pre-op ther.in postmenopaus.women with localis.horm.recept.  Degarelix  of in utero death foetus.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page348.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page344.html">344</a>&nbsp;&nbsp;&nbsp;<a href="page345.html">345</a>&nbsp;&nbsp;&nbsp;<a href="page346.html">346</a>&nbsp;&nbsp;&nbsp;<a href="page347.html">347</a>&nbsp;&nbsp;&nbsp;<a href="page348.html">348</a>&nbsp;&nbsp;&nbsp;<a href="page349.html">349</a>&nbsp;&nbsp;&nbsp;<a href="page350.html">350</a>&nbsp;&nbsp;&nbsp;<a href="page351.html">351</a>&nbsp;&nbsp;&nbsp;<a href="page352.html">352</a>&nbsp;&nbsp;&nbsp;<a href="page353.html">353</a>&nbsp;&nbsp;&nbsp;<a href="page354.html">354</a>
             </td>
             <td width="35%"><a href="page350.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page350.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
